1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023
Yuengling K, Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde A, Gibbs K, Prekker M, Mohamed A, Johnson N, Peltan I, Bender W, Mallow C, Kwon J, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Swan S, Johnson C, McMorrow M, Self W, Martin E. 1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.081. PMCID: PMC10678102, DOI: 10.1093/ofid/ofad500.081.Peer-Reviewed Original ResearchInvasive mechanical ventilationAcute respiratory illnessAdvanced respiratory supportSARS-CoV-2Respiratory supportRespiratory illnessCOVID-19Use of IMVHigh-flow nasal cannulaMultivariable logistic regression modelAsahi Kasei PharmaMedical condition categoriesSeverity of RSVFlow nasal cannulaInfluenza-associated hospitalizationsNon-invasive ventilationShortness of breathSeverity of illnessRespiratory syncytial virusSevere respiratory illnessGrant/research supportChi-square testLogistic regression modelsPrevalence of RSVMedian age2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
DeCuir J, Zhu Y, Gaglani M, Ginde A, Mohr N, Gibbs K, Hager D, Frosch A, Mohamed A, Johnson N, Steingrub J, Peltan I, Martin E, Bender W, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Womack K, Swan S, McMorrow M, Self W, Surie D. 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.153. PMCID: PMC10677158, DOI: 10.1093/ofid/ofad500.153.Peer-Reviewed Original ResearchCOVID-19-associated hospitalizationRelative vaccine effectivenessVaccine effectivenessBooster doseSARS-CoV-2Hospitalized adultsIllness onsetDays of receiptCOVID-19 vaccination seriesCOVID-19-like illnessAdditional booster dosesAsahi Kasei PharmaMRNA vaccine effectivenessMultivariable logistic regressionHuman Services (HHS) regionsCase-control analysisUnvaccinated patientsVaccination seriesBooster dosesImmunization PracticesMRNA vaccinationAdults AgedRespiratory virusesAntigen testAdmission date